- Home
- DAWN vs NBBK Comparison
DAWN vs NBBK Comparison
Compare DAWN & NBBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DAWN | NBBK |
|---|---|---|
| Founded | 2018 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DAWN | NBBK |
|---|---|---|
| Price | $21.20 | $20.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 1 |
| Target Price | ★ $27.11 | $23.00 |
| AVG Volume (30 Days) | ★ 2.3M | 310.3K |
| Earning Date | 05-25-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.32% |
| EPS Growth | N/A | ★ 25.23 |
| EPS | N/A | ★ 1.34 |
| Revenue | ★ $158,182,000.00 | N/A |
| Revenue This Year | $53.52 | $43.56 |
| Revenue Next Year | $27.10 | $31.58 |
| P/E Ratio | ★ N/A | $15.85 |
| Revenue Growth | ★ 20.60 | N/A |
| 52 Week Low | $5.64 | $15.09 |
| 52 Week High | $13.20 | $22.70 |
Technical Indicators
Market Signals| Indicator | DAWN | NBBK |
|---|---|---|
| Relative Strength Index (RSI) | 82.69 | 43.40 |
| Support Level | $6.40 | $19.43 |
| Resistance Level | N/A | $22.65 |
| Average True Range (ATR) | 0.77 | 0.70 |
| MACD | 0.65 | -0.15 |
| Stochastic Oscillator | 99.73 | 22.38 |
Price Performance
Historical ComparisonAbout DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.